{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:34:27Z","timestamp":1791221667958,"version":"4.1.0"},"reference-count":47,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019573","name":"Amsterdam University Medical Centers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002066","name":"GlaxoSmithKline foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Patients with Non\u2010steroidal anti\u2010inflammatory drugs (\n                      <jats:styled-content style=\"fixed-case\">NSAID<\/jats:styled-content>\n                      )\u2010Exacerbated Respiratory Disease (N\u2010\n                      <jats:styled-content style=\"fixed-case\">ERD<\/jats:styled-content>\n                      ) can suffer from difficult\u2010to\u2010treat primary diffuse type 2 chronic rhinosinusitis with nasal polyps (\n                      <jats:styled-content style=\"fixed-case\">CRSwNP<\/jats:styled-content>\n                      ). This study evaluates dupilumab effectiveness and dose tapering in\n                      <jats:styled-content style=\"fixed-case\">CRSwNP<\/jats:styled-content>\n                      patients with N\u2010\n                      <jats:styled-content style=\"fixed-case\">ERD<\/jats:styled-content>\n                      compared to those without.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A real\u2010world prospective cohort with\n                      <jats:styled-content style=\"fixed-case\">CRSwNP<\/jats:styled-content>\n                      patients, with N\u2010\n                      <jats:styled-content style=\"fixed-case\">ERD<\/jats:styled-content>\n                      or without (\n                      <jats:styled-content style=\"fixed-case\">CRSwNP<\/jats:styled-content>\n                      \u2010\n                      <jats:styled-content style=\"fixed-case\">NOS<\/jats:styled-content>\n                      ; not otherwise specified), aged \u2265\u200918 treated with dupilumab 300\u2009mg subcutaneously every 2\u2009weeks. In case of clinical control, the interdose interval was prolonged every 6\u2009months with steps of 2\u2009weeks. (Clinical) data were collected at baseline, 24\u2009weeks, and 2\u2009years of treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Most baseline characteristics, including Nasal Polyp Score (\n                      <jats:styled-content style=\"fixed-case\">NPS<\/jats:styled-content>\n                      ), Sino\u2010Nasal Outcome Test\u201022 (\n                      <jats:styled-content style=\"fixed-case\">SNOT<\/jats:styled-content>\n                      \u201022), and Sniffin\u2032 sticks\u201012 test (\n                      <jats:styled-content style=\"fixed-case\">SSIT<\/jats:styled-content>\n                      \u201012) were comparable between groups (N\u2010\n                      <jats:styled-content style=\"fixed-case\">ERD<\/jats:styled-content>\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009105,\n                      <jats:styled-content style=\"fixed-case\">CRSwNP<\/jats:styled-content>\n                      \u2010\n                      <jats:styled-content style=\"fixed-case\">NOS<\/jats:styled-content>\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009293). There was a higher prevalence (91.5% vs. 71.1%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) but comparable control of asthma in N\u2010\n                      <jats:styled-content style=\"fixed-case\">ERD<\/jats:styled-content>\n                      patients (asthma control test [\n                      <jats:styled-content style=\"fixed-case\">ACT]<\/jats:styled-content>\n                      : N\u2010\n                      <jats:styled-content style=\"fixed-case\">ERD<\/jats:styled-content>\n                      66.7% less controlled\/uncontrolled vs.\n                      <jats:styled-content style=\"fixed-case\">CRSwNP<\/jats:styled-content>\n                      \u2010\n                      <jats:styled-content style=\"fixed-case\">NOS<\/jats:styled-content>\n                      58.3%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.21). All outcomes improved significantly with dupilumab treatment at 24\u2009weeks and remained improved after 2\u2009years, without intergroup differences (median scores at 24\u2009weeks for N\u2010\n                      <jats:styled-content style=\"fixed-case\">ERD<\/jats:styled-content>\n                      patients vs.\n                      <jats:styled-content style=\"fixed-case\">CRSwNP<\/jats:styled-content>\n                      \u2010\n                      <jats:styled-content style=\"fixed-case\">NOS<\/jats:styled-content>\n                      , respectively:\n                      <jats:styled-content style=\"fixed-case\">NPS<\/jats:styled-content>\n                      : 2 vs. 1,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.65;\n                      <jats:styled-content style=\"fixed-case\">SNOT<\/jats:styled-content>\n                      \u201022: 18 vs. 19,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.27;\n                      <jats:styled-content style=\"fixed-case\">SSIT<\/jats:styled-content>\n                      \u201012: 7 vs. 8,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02;\n                      <jats:styled-content style=\"fixed-case\">ACT<\/jats:styled-content>\n                      : 21 vs. 22,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.11). Dose tapering was possible in the majority of patients, with almost half at an 8\u201312\u2009weeks interval in both groups after 2\u2009years.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Dupilumab shows comparable effectiveness and taper feasibility between\n                      <jats:styled-content style=\"fixed-case\">CRSwNP<\/jats:styled-content>\n                      N\u2010\n                      <jats:styled-content style=\"fixed-case\">ERD<\/jats:styled-content>\n                      patients and\n                      <jats:styled-content style=\"fixed-case\">CRSwNP<\/jats:styled-content>\n                      \u2010\n                      <jats:styled-content style=\"fixed-case\">NOS<\/jats:styled-content>\n                      patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/all.16579","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T09:02:02Z","timestamp":1747386122000},"page":"1737-1745","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Two\u2010Year Data of Tapered Dupilumab Shows High Effectiveness in Chronic Rhinosinusitis with Nasal Polyps With Nonsteroidal Anti\u2010inflammatory Drug\u2010Exacerbated Respiratory Disease"],"prefix":"10.1111","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8576-6018","authenticated-orcid":false,"given":"H. B. E.","family":"Elzinga","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery Amsterdam UMC, University of Amsterdam  Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5437-3005","authenticated-orcid":false,"given":"J. J.","family":"Otten","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery Amsterdam UMC, University of Amsterdam  Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Cornet","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology Alrijne Hospital  Leiden the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. B.","family":"Rinia","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology Isala Hospital  Zwolle the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J. L.","family":"Van Der Lans","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery Amsterdam UMC, University of Amsterdam  Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4852-229X","authenticated-orcid":false,"given":"W. J.","family":"Fokkens","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery Amsterdam UMC, University of Amsterdam  Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1734-2632","authenticated-orcid":false,"given":"S.","family":"Reitsma","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery Amsterdam UMC, University of Amsterdam  Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"PolyREG Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13599"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.020"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcibr1514013"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-020-00905-9"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1487"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-017-0673-6"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.12.027"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2012.11.002"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2021.734000"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2016.06.007"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.09.011"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31881-1"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.05.032"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00097-7"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15772"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin23.357"},{"issue":"4","key":"e_1_2_10_18_1","first-page":"403","article-title":"Steroid Responsiveness Predicts Olfactory Function Recovery in Dupilumab Treated CRSwNP","volume":"62","author":"Otten J. J.","year":"2024","journal-title":"Rhinology"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15796"},{"issue":"1","key":"e_1_2_10_20_1","first-page":"10","article-title":"Dupilumab Reduces Opacification Across All Sinuses and Related Symptoms in Patients With CRSwNP","volume":"58","author":"Bachert C.","year":"2020","journal-title":"Rhinology"},{"issue":"3","key":"e_1_2_10_21_1","first-page":"203","article-title":"Dupilumab for Chronic Rhinosinusitis With Nasal Polyps: Real\u2010Life Retrospective 12\u2010Month Effectiveness Data","volume":"61","author":"Boscke R.","year":"2023","journal-title":"Rhinology"},{"issue":"3","key":"e_1_2_10_22_1","first-page":"301","article-title":"Dupilumab Reduces Systemic Corticosteroid Use and Sinonasal Surgery Rate in CRSwNP","volume":"59","author":"Desrosiers M.","year":"2021","journal-title":"Rhinology"},{"issue":"4","key":"e_1_2_10_23_1","first-page":"410","article-title":"Real\u2010Life Effectiveness of Dupilumab in Chronic Rhinosinusitis With Nasal Polyps. Results From Eight Hungarian Centres With 12\u2010Month Follow\u2010Up","volume":"62","author":"Kiricsi A.","year":"2024","journal-title":"Rhinology"},{"issue":"2","key":"e_1_2_10_24_1","first-page":"148","article-title":"Respiratory Epithelial Adenomatoid Hamartoma With Nasal Polyps Affects Dupilumab Efficacy","volume":"60","author":"Takeda T.","year":"2022","journal-title":"Rhinology"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S391896"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15222"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15067"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01335-2022"},{"issue":"3","key":"e_1_2_10_29_1","first-page":"383","article-title":"Eosinophils Are the Dominant type2 Marker for the Current Indication of Biological Treatment in Severe Uncontrolled Chronic Rhinosinusitis With Nasal Polyps","volume":"62","author":"Lans R.","year":"2024","journal-title":"Rhinology"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15134"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin20.600"},{"issue":"3","key":"e_1_2_10_32_1","first-page":"194","article-title":"EPOS\/EUFOREA Update on Indication and Evaluation of Biologics in Chronic Rhinosinusitis With Nasal Polyps 2023","volume":"61","author":"Fokkens W. J.","year":"2023","journal-title":"Rhinology"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/000348940111001015"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-4486.2009.01995.x"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.07.040"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.09.008"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/coa.13177"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.06.053"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.29888"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2024.03.011"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.07.004"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.11.037"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.2500\/ajra.2009.23.3325"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1067\/mhn.2002.121913"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12131"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-35002"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091\u20106749(84)90361\u20100"},{"issue":"4","key":"e_1_2_10_48_1","first-page":"385","article-title":"Revision Surgery, Biologics, or Both?","volume":"62","author":"Fokkens W. J.","year":"2024","journal-title":"Rhinology"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/all.16579","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T12:06:24Z","timestamp":1754913984000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/all.16579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/all.16579"],"URL":"https:\/\/doi.org\/10.1111\/all.16579","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"2024-12-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}